Marfan syndrome: Clinical diagnosis and management

European Journal of Human Genetics

Volumn 15, Issue 7, 2007, Pages 724-733

  Dean, John C S ^a  

^a NHS GRAMPIAN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHETIC AGENT; ANTICOAGULANT AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FIBRILLIN; LOSARTAN; PROPRANOLOL; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2;

ANEURYSM SURGERY; AORTA DISSECTION; ARTICLE; ARTIFICIAL VENTILATION; BACKACHE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR SURGERY; CENTRAL NERVOUS SYSTEM DISEASE; CHROMOSOME 15; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DNA DETERMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ECHOGRAPHY; ECTOPIA LENTIS; ELECTROCARDIOGRAPHY; EXERCISE; EYE DISEASE; EYE SURGERY; FAMILY HISTORY; FAMILY STUDY; GENE MUTATION; GENETIC CODE; GENETIC RISK; GENETIC SCREENING; HUMAN; LUNG SURGERY; MARFAN SYNDROME; MEDICAL ASSESSMENT; MOLECULAR GENETICS; MUSCULOSKELETAL DISEASE; MUTATIONAL ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PENETRANCE; PHENOTYPE; PRACTICE GUIDELINE; PREGNANCY COMPLICATION; PRIORITY JOURNAL; REFRACTION ERROR; RESPIRATORY TRACT DISEASE; RISK ASSESSMENT; RISK FACTOR; SKIN DISEASE; SPORT INJURY; THORACIC AORTA ANEURYSM; VISUAL SYSTEM EXAMINATION;

ADOLESCENT; ADULT; ALGORITHMS; CARDIOVASCULAR DISEASES; CHILD; CHILD, PRESCHOOL; EYE DISEASES; FEMALE; HUMANS; INFANT, NEWBORN; MALE; MARFAN SYNDROME; MICROFILAMENT PROTEINS; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 34250869487     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/sj.ejhg.5201851     Document Type: Article

References (73)

1. Gray JR, Bridges AB, West RR et al: Life expectancy in British Marfan syndrome populations. Clin Genet 1998; 54: 124-128.
2. Dietz HC, Cutting GR, Pyeritz RE et al: Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature 1991; 352: 337-339.
3. Dietz HC, Pyeritz RE: Mutations in the human gene for fibrillin-1 (FBN1) in the Marfan syndrome and related disorders. Hum Mol Genet 1995; 4: 1799-1809.
4. Loeys B, Nuytinck L, Delvaux I, De Bie S, De Paepe A: Genotype and phenotype analysis of 171 patients referred for molecular study of the fibrillin-1 gene FBN1 because of suspected Marfan syndrome. Arch Intern Med 2001; 161: 2447-2454.
5. Loeys B, De Backer J, Acker P et al: Comprehensive molecular screening of the FBN1 gene favors locus homogeneity of classical Marfan syndrome. Hum Mutat 2004; 24: 140-146.
6. Mizuguchi T, Collod-Beroud G, Akiyama T et al: Heterozygous TGFBR2 mutations in Marfan syndrome. Nat Genet 2004; 36: 855-860.
7. Singh KK, Rommel K, Mishra A et al: TGFBR1 and TGFBR2 mutations in patients with features of Marfan syndrome and Loeys-Dietz syndrome. Hum Mutat 2006; 27: 770-777.
8. Sakai H, Visser R, Ikegawa S et al: Comprehensive genetic analysis of relevant four genes in 49 patients with Marfan syndrome or Marfan-related phenotypes. Am J Med Genet A 2006; 140: 1719-1725.
9. Mizuguchi T, Matsumoto N: Recent progress in genetics of Marfan syndrome and Marfan-associated disorders. J Hum Genet 2007; 52: 1-12.
10. Pannu H, Fadulu VT, Chang J et al: Mutations in transforming growth factor-beta receptor type II cause familial thoracic aortic aneurysms and dissections. Circulation 2005; 112: 513-520.
11. Law C, Bunyan D, Castle B et al: Clinical features in a family with an R460H mutation in transforming growth factor beta receptor 2 gene. J Med Genet 2006; 43: 908-916.
12. Loeys BL, Chen J, Neptune ER et al: A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet 2005; 37: 275-281.
13. Loeys BL, Schwarze U, Holm T et al: Aneurysm syndromes caused by mutations in the TGF-beta receptor. N Engl J Med 2006; 355: 788-798.
14. De Paepe A, Devereux RB, Dietz HC, Hennekam RC, Pyeritz RE: Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet 1996; 62: 417-426.
15. Campbell H, Bradshaw N, Davidson R et al: Evidence based medicine in practice: Lessons from a Scottish clinical genetics project. J Med Genet 2000; 37: 684-691.
16. SIGN Guideline Development Handbook (SIGN50): Scottish Intercollegiate Guidelines Network, March 2004, http://www.sign.ac.uk/methodology/index.html.
17. Roman MJ, Rosen SE, Kramer-Fox R, Deverereux RB: Prognostic significance of the pattern of aortic root dilation in the Marfan syndrome. J Am Coll Cardiol 1993; 22: 1470-1476.
18. Yule SR, Hobson EE, Dean JCS, Gilbert FJ: Protrusio acetabuli in Marfan's syndrome. Clin Radiol 1999; 54: 95-97.
19. Shores J, Berger KR, Murphy EA, Pyeritz RE: Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. N Engl J Med 1994; 330: 1335-1341.
20. Lipscomb KJ, Clayton-Smith J, Harris R: Evolving phenotype of Marfan's syndrome. Arch Dis Child 1997; 76: 41-46.
21. Joseph KN, Kane HA, Milner RS, Steg NL, Williamson MB, Bowen JR: Orthopedic aspects of the Marfan phenotype. Clin Orthop Relat Res 1992; 277: 251-261.
22. Gelb BD: Marfan's syndrome and related disorders - more tightly connected than we thought. New Engl J Med 2006; 355: 841-844.
23. Dietz HC, Loeys B, Carta L, Ramirez F: Recent progress towards a molecular understanding of Marfan syndrome. Am J Med Genet C Semin Med Genet 2005; 139: 4-9.
24. Habashi JP, Judge DP, Holm TM et al: Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006; 312: 117-121.
25. Groenink M, Lohuis TAJ, Tijssen JG et al: Survival and complication free survival in Marfan's syndrome: Implications of current guidelines. Heart 1999; 82: 499-504.
26. Legget ME, Unger TA, O'Sullivan CK et al: Aortic root complications in Marfan's syndrome: Identification of a lower risk group. Heart 1996; 75: 389-395.
27. Meijboom LJ, Timmermans J, Zwinderman AH, Engelfriet PM, Mulder BJ: Aortic root growth in men and women with the Marfan's syndrome. Am J Cardiol 2005; 96: 1441-1444.
28. Rios AS, Silber EN, Bavishi N, Burton BK, Clark WA, Denes P: Effect of long-term beta-blockade on aortic root compliance in patients with Marfan syndrome. Am Heart J 1999; 137: 1057-1061.
29. Adams JN, Brooks M, Redpath TW et al: Aortic distensibility and stiffness index measured by magnetic resonance imaging in patients with Marfan's syndrome. Br Heart J 1995; 73: 265-269.
30. Salim MA, Alpert BS, Ward JC, Pyeritz RE: Effect of beta-adrenergic blockade on aortic root rate of dilation in the Marfan syndrome. Am J Cardiol 1994; 74: 629-633.
31. Haouzi A, Berglund H, Pelikan PCD, Maurer G, Siegel RJ: Heterogeneous aortic response to acute beta-adrenergic blockade in Marfan syndrome. Am Heart J 1997; 133: 60-63.
32. Groenink M, de Roos A, Mulder BJM, Spaan JAE, van der Wall EE: Changes in aortic distensibility and pulse wave velocity assessed with magnetic resonance imaging following beta-blocker therapy in the Marfan syndrome. Am J Cardiol 1998; 82: 203-208.
33. Rossi-Foulkes R, Roman MJ, Rosen SE et al: Phenotypic features and impact of beta blocker or calcium agonist therapy on aortic lumen size in the Marfan syndrome. Am J Cardiol 1999; 83: 1364-1368.
34. Nagashima H, Sakomura Y, Aoka Y et al: Angiotensin II type 2 receptor mediates muscle cell apoptosis in cystic medical degeneration associated with Marfan's syndrome. Circulation 2001; 104 (Suppl I): I-282-I-287.
35. Yetman AT, Bornemeier AT, McCrindle BW: Usefulness of enalapril versus propranolol or atenolol for prevention of aortic dilation in patients with the Marfan syndrome. Am J Cardiol 2005; 95: 1125-1127.
36. Wilson DG, Bellamy MF, Ramsey MW et al: Endothelial function in Marfan syndrome. Circulation 1999; 99: 909-915.
37. Meijboom LJ, Nollen GJ, Mulder BJM: Prevention of cardiovascular complications in the Marfan syndrome. Vasc Dis Prev 2004; 1: 79-86.
38. Gott VL, Greene PS, Alejo DE et al: Replacement of the aortic root in patients with Marfan's syndrome. N Engl J Med 1999; 340: 1307-1313.
39. Finkbohner R, Johnston D, Crawford S, Coselli J, Milewicz DM: Marfan syndrome. Long-term survival and complications after aortic aneurysm repair. Circulation 1995; 91: 728-733.
40. de Oliveira NC, David TE, Ivanov J et al: Results of surgery for aortic root aneurysm in patients with Marfan syndrome. J Thorac Cardiovasc Surg 2003; 125: 789-796.
41. Nataf P, Lansac E: DilatatioM of the thoracic aorta: medical and surgical management. Heart 2006; 92: 1345-1352.
42. Treasure T: Elective replacement of the aortic root in Marfan's syndrome. Br Heart J 1993; 69: 101-103.
43. Bassano C, De Matteis GM, Nardi P et al: Mid-term follow-up of aortic root remodelling compared to Bentall operation. Eur J Cardio-Thorac Surg 2001; 19: 601-605.
44. Kallenbach K, Karck M, Pak D et al: Decade of aortic valve sparing reimplantation: Are we pushing the limits too far? Circulation 2005; 112 (Suppl 9): I253-I259.
45. van den Berg JS, Limburg M, Hennekam RC: Is Marfan syndrome associated with symptomatic intracranial aneurysms? Stroke 1996; 27: 10-12.
46. Maumenee IH: The eye in the Marfan syndrome. Tr Am Ophth Soc 1981; 79: 684-733.
47. Pyeritz RE, McKDsick VA: The Marfan syndrome: diagnosis and management. N Engl J Med 1979; 300: 772-777.
48. Hubbard AD, Charteris DG, Cooling RJ: Vitreolensectomy in Marfan's syndrome. Eye 1998; 12: 412-416.
49. Pyeritz RE, Francke U: The second international symposium on the Marfan syndrome. Am J Med Genet 1993; 47: 127-135.
50. Fattori R, Nienaber CA, Descovich B et al: Importance of dural ectasia in phenotypic assessment of Marfan's syndrome. Lancet 1999; 354: 910-913.
51. Oosterhof T, Groenink M, Hulsmans FJ et al: Quantitative assessment of dural ectasia as a marker for Marfan syndrome. Radiology 2001; 220: 514-518.
52. Ahn NU, Sponseller PD, Ahn UM, Nallamshetty L, Kuszyk BS, Zinreich SJ: Dural ectasia is associated with back pain in Marfan syndrome. Spine 2000; 25: 1562-1568.
53. Le Parc JM, Molcard S, Tubach F: Bone mineral density in Marfan syndrome. Rheumatology (Oxford) 2001; 40: 358-359.
54. Giampietro PF, Peterson M, Schneider R et al: Assessment of bone mineral density in adults and children with Marfan syndrome. Osteoporos Int 2003; 14: 559-563.
55. Grahame R, PyerJtz RE: The Marfan syndrome: joint and skin manifestations are prevalent and correlated. Br J Rheumatol 1995; 34: 126-131.
56. Behan WM, Longman C, Petty RK et al: Muscle fibrillin deficiency in Marfan's syndrome myopathy. J Neurol Neurosurg Psychiatry 2003; 74: 633-638.
57. Scherer LR, Arn PH, Dressel DA, Pyeritz RM, Haller Jr JA: Surgical management of children and young adults with Marfan syndrome. J Pediatr Surg 1988; 23: 1169-1172.
58. Streeten EA, Murphy EA, Pyeritz RE: Pulmonary function in the Marfan syndrome. Chest 1987; 91: 408-412.
59. Golladay ES, Char F, Mollitt DL: Children with Marfan's syndrome and pectus excavatum. Southern Med J 1985; 78: 1319-1323.
60. Arn PH, Scherer LR, Haller Jr JA, Pyeritz RE: Outcome of pectus excavatum in patients with Marfan syndrome and in the general population. J Pediatr 115; 1989: 957-958.
61. Hall JR, Pyeritz RE, Dudgeon DL, Haller JA: Pneumothorax in the Marfan syndrome: Prevalence and therapy. Ann Thorac Surg 1984; 37: 500-504.
62. Wood JR, Bellamy D, Child AH, Citron KM: Pulmonary disease in patients with Marfan syndrome. Thorax 1984; 39: 780-784.
63. Cistulli PA, Gotsopoulos H, Sullivan CE: Relationship between Craniofacial abnormalities and sleep-disordered breathing in Marfan's syndrome. Chest 2001; 120: 1455-1460.
64. Lacassie AJ, Millar S, Leithe LG, Muir et al: Dural ectasia: a likely cause of inadequate spinal anaesthesia in two parturients with Marfan's syndrome. Br J Anaesth 2005; 94: 500-504.
65. Rosser T, Finkel J, Vezina G, Majd M: Postural headache in a child with Marfan syndrome: Case report and review of the literature. J Child Neurol 2005; 20: 153-155.
66. Voyvodic F, Scroop R, Sanders RR: Anterior sacral meningocele as a pelvic complication of Marfan syndrome. Aust NZ J Obstet Gynaecol 1999; 39: 262-265.
67. Wityk RJ, Zanferrari C, Oppenheimer S: Neurovascular complications of Marfan syndrome: A Retrospective, Hospital-Based Study. Stroke 2002; 33: 680-684.
68. Immer FF, Bansi AG, Immer-Bansi AS et al: Aortic dissection in pregnancy: Analysis of risk factors and outcome. Ann Thorac Surg 2003; 76: 309-314.
69. Chow SL: Acute aortic dissection in a patient with Marfan's syndrome complicated by gestational hypertension. Med J Aust 1993; 159 760-762.
70. Lind J, Wallenburg HCS: The MArfan syndrome and pregnancy: a retrospective study in a Dutch population. Eur J Obstet Gynaecol Reprod Biol 2001; 98: 28-35.
71. Meijboom LJ, Drenthen W, Pieper PG et al: On behalf of the ZAHARA investigators. Obstetric complications in Marfan syndrome. Int J Cardiol 2006; 110: 53-59.
72. Salim MA, Alpert BS: Sports and Marfan syndrome - awareness and early diagnosis can prevent sudden death. Phys Sportsmed 2001; 29: 80-93 (http://www.physsportsmed.com/issues/2001/05_01/salim.htm).
73. Maron BJ, Chaitman BR, Ackerman MJ et al: Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation 2004; 109: 2807-2816.